MedTrace Logo

Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain

NCT02100956 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-10-03

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine the effect of oxytocin given into the spinal fluid on pain and areas and intensity of hyperalgesia and allodynia in patients with chronic neuropathic pain.

Conditions

  • Neuropathic Pain

Interventions

DRUG

oxytocin 100 micrograms

oxytocin 100 micrograms administered intrathecally (IT)

DRUG

Normal Saline (preservative free)

Normal Saline (preservative free) administered intrathecally (IT)

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • James C. Eisenach, M.D. · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-19
Primary Completion
2022-10-10
Completion
2022-10-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02100956 on ClinicalTrials.gov